Results for: Ataccept

Vera Therapeutics announced positive long-term data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), showcasing stabilized kidney function and a favorable safety profile. The results, presented at Kidney Week 2024 and published in the Journal of the American Society of Nephrology, further support the potential of atacicept as a long-term IgAN treatment and bolster confidence in the ongoing Phase 3 trial. The company is also planning to initiate an extension study to provide continued access to atacicept before commercial availability.

Vera Therapeutics has released promising long-term data from its ORIGIN Phase 2b trial, showing that atacicept, a B-cell modulator, can effectively stabilize kidney function in patients with immunoglobulin A nephropathy (IgAN). This suggests a potential for preventing kidney failure in these individuals. The data, presented at the American Society of Nephrology Kidney Week 2024 and published in the Journal of the American Society of Nephrology, highlight atacicept’s disease-modifying capabilities and pave the way for a potential best-in-class treatment option for IgAN.